Six years survival on imatinib with no disease progression after diagnosis of metastatic duodenal gastrointestinal stromal tumour: A case report

Article English OPEN
Bhattacharya, Sayantan ; Choudhury, Amit Kumar ; Ravi, Srinivasan ; Morrissey, John ; Mathew, George (2008)

Introduction: A duodenal Gastrointestinal Stromal Tumour (GIST) is a rare finding and until recently advanced disease had a poor prognosis. A PubMed search revealed no reports of more than five years survival of inoperable GIST on chemotherapy with WHO performance status zero.\ud Case Presentation: A 68 year old female was diagnosed with unresectable GIST in the duodenum with metastasis to liver, pancreas and omentum in November 2001. She was\ud commenced on imatinib mesylate (Glivec) chemotherapy. This case report was prepared from the medical records and radiology reports. She had good tolerance with stable disease. After six years her CT scan showed no disease progression and her WHO performance status was zero.\ud Conclusion: This report supports the view that imatinib is a safe and effective drug in controlling\ud disease progression in advanced metastatic GIST and plays an important role in improving the patient's quality of life.
  • References (8)

    World Journal of Gastroenterology 12(17):2793-7. 2006 May 7; National Institute for Clinical Excellence: Imatinib for the treatment of unresectable and/or metastatic gastro-intestinal stromal tumours. Technology Appraisal Guidance 86, Guidelines on GIST [http://www.nice.org.uk/TA086guidance].

    Miettinen M, Lasota J: Gastrointestinal stromal tumors: pathology and prognosis at different sites. Seminars in diagnostic pathology 2006, 23(2):70-83.

    Bearzi I, Mandolesi A, Arduini F, Costagliola A, Ranaldi R: Gastrointestinal stromal tumor. A study of 158 cases: clinicopathological features and prognostic factors. Analytical and Quantitative Cytology and Histology/The International Academy of Cytology (and) American Society of Cytology 2006, 28(3):137-47.

    Emile JF, Tabone-Eqlinqer S, Theou-Anton N, Lemoine A: Prognostic value of KIT exon 11 deletions in GISTs. Gastroenterology 2006, 131(3):976-8.

    Martin J, Poveda A, Llombart-Bosch A, Ramos R, Lopez-Guerrero JA, Garcia del Muro J, Maurel J, Calabuig S, Guttierrez A, Gonzalez de Sande JL, Martinez J, De Juan A, Lainez N, Losa F, Alija V, Escudero P, Casado A, Garcia P, Blanco R, Buesa JM, Spanish Group for Sarcoma Research: Deletions affecting codons 557-558 of the c-KIT gene indicate a poor prognosis in patients with completely resected gastrointestinal stromal tumors: a study by the Spanish Group for Sarcoma Research (GEIS). Journal of clinical oncology 23(25):6190-8. 2005 Sep 1; Singer S, Rubin BP, Lux ML, Chen CJ, Demetri GD, Fletcher CD, Fletcher JA: Prognostic value of KIT mutation type, mitotic activity and histologic subtype in gastrointestinal stromal tumors. Journal of clinical oncology 20(18):3898-905. 2002 Sep 15; Andersson J, Bumming P, Meis-Kindblom JM, Sihto H, Nupponen N, Joensuu H, Oden A, Gustavsson B, Kindblom LG, Nilsson B: Gastrointestinal stromal tumors with KIT exon11 deletions are associated with poor prognosis. Gastroenterology 2006, 130(6):1573-81.

    Heinrich MC, Corless CL, Blanke CD, Demetri GD, Joensuu H, Roberts PJ, Eisenberg BL, von Mehren M, Fletcher CD, Sandau K, McDougall K, Ou WB, Chen CJ, Fletcher JA: Molecular correlates of 1.

    imatinib resistance in gastrointestinal stromal tumors. Journal of Clinical Oncology 24(29):4764-74. 2006 Oct 10; 10. Hornick JL, Fletcher CD: The role of KIT in the management of patients with gastrointestinal stromal tumours. Human Pathology 2007, 38(5):679-87.

    11. Lasota J, Miettinen M: KIT and PDGFRA mutations in gastrointestinal stromal tumors (GISTs). Seminars in diagnostic pathology 2006, 23(2):91-102.

  • Metrics
    No metrics available
Share - Bookmark